BusinessCellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical TrialBy Nasdaq OMXApr 10, 2018, 11:01 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory AffairsBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessSummit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical ConferenceBy Nasdaq OMXMar 14, 2018, 11:00 AM UTC
BusinessActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXMar 13, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at 30th Annual ROTH ConferenceBy Nasdaq OMXMar 7, 2018, 12:30 PM UTC
BusinessSummit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional GroupBy Nasdaq OMXMar 7, 2018, 12:02 PM UTC
BusinessActinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 28, 2018, 12:30 PM UTC
BusinessAchillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 GlomerulopathyBy Nasdaq OMXFeb 26, 2018, 11:05 AM UTC
